Omeros (OMER)
(Delayed Data from NSDQ)
$4.87 USD
-0.15 (-2.99%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $4.85 -0.02 (-0.41%) 7:22 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 101 - 120 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
Omeros Receives Authorization for OMS527 Clinical Testing Initiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Another Potential OMIDRIA Generic Entrant Evaded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Omeros Corporation
Industry: Medical - Products
Q1 Financials; Financial Risk Persists but Clarity on OMS721 Increases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
1Q 2018 Results Reported; Slight Revenue Miss, Bottom Line In-Line; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Second Breakthrough Therapy Designation for OMS721; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Q1 Preview; Bloomberg Estimates Q1 Earnings Release on May 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Revenue Projections Revised; Debt Covenants Relaxed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
Fostamatinib IgAN Setback Improves Competitive Landscape for OMS721; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Downgrading to NEUTRAL Due to Unclear Finances and OMS721 Phase 3 Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Omeros Corporation
Industry: Medical - Products
OMIDRIA Pass-Through Reimbursement Status Extended; Reiterate Buy and Raising Target to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
4Q and FY2017 Financial Results Reported; OMIDRIA Revenues Decline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Updating OMIDRIA Estimates; Putting Things in Perspective; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
OMS721 Treatment Boosts Overall Survival in Thrombotic Microangiopathy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Omeros Corporation
Industry: Medical - Products
Phase 2 Data Shows Improved Survival in HCT-TMA Patients
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L